A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Summary

This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

Timeline

Start

2022-06-22

Primary completion

2024-05-30

Completion

2024-11-30

Publications

• Chen J, Shen Z, Jiang X, Huang Z, Wu C, Jiang D, Yin L. Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Ralpha complex. Antib Ther. 2022 Nov 17;6(1):38-48. doi: 10.1093/abt/tbac031. eCollection 2023 Jan.

Drugs

Indications